Id: acc0676
Group: 1sens
Protein: RUNX1
Gene Symbol: RUNX1
Protein Id: Q01196
Protein Name: RUNX1_HUMAN
PTM: phosphorylation
Site: Ser94
Site Sequence: LPIAFKVVALGDVPDGTLVTV
Disease Category: Cancer
Disease: Leukemia
Disease Subtype: CML
Disease Cellline:
Disease Info:
Drug: imatinib
Drug Info: "Imatinib is a tyrosine kinase inhibitor that targets Bcr-Abl and KIT proteins, used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST)."
Effect: inhibit
Effect Info: Metformin can inhibit STAT3 phosphorylation through AMPK - induced RUNX1 (Ser94) phosphorylation and enhance imatinib sensitivity in imatinib - resistant subjects.
Note:
Score: 5.0
Pubmed(PMID): 37903788
Sentence Index:
Sentence:

Sequence & Structure:

MRIPVDASTSRRFTPPSTALSPGKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFLCSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNATAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSISDPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQGGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSALLNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

RUNX1-Ser17
Cancer Intensity
BRCA
COAD 0.196
HGSC 1.773
ccRCC -0.488
GBM -0.998
HNSC -0.027
LUAD -1.089
LUSC
non_ccRCC
PDAC
UCEC 0.632
RUNX1-Ser193
Cancer Intensity
BRCA 0.707
COAD
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RUNX1-Ser21
Cancer Intensity
BRCA -2.457
COAD 0.432
HGSC 0.165
ccRCC 0.607
GBM 0.05
HNSC 0.7
LUAD -0.021
LUSC 0.389
non_ccRCC -1.291
PDAC 0.878
UCEC 0.548
RUNX1-Ser212
Cancer Intensity
BRCA -1.606
COAD -1.106
HGSC 0.909
ccRCC 0.257
GBM 0.212
HNSC 1.488
LUAD -0.2
LUSC 0.596
non_ccRCC -1.3
PDAC 0.958
UCEC -0.209
RUNX1-Ser249
Cancer Intensity
BRCA
COAD
HGSC -1.611
ccRCC
GBM 0.72
HNSC 0.549
LUAD -0.342
LUSC
non_ccRCC
PDAC
UCEC 0.683
RUNX1-Ser257
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC 0.707
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
RUNX1-Ser263
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC -0.243
LUAD -0.856
LUSC
non_ccRCC
PDAC
UCEC 1.099
RUNX1-Ser268
Cancer Intensity
BRCA
COAD
HGSC -1.271
ccRCC
GBM 0.193
HNSC -0.08
LUAD
LUSC
non_ccRCC
PDAC
UCEC 1.158
RUNX1-Ser50
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD 0.707
LUSC
non_ccRCC
PDAC -0.707
UCEC
RUNX1-Thr14
Cancer Intensity
BRCA 0.412
COAD -0.055
HGSC 1.822
ccRCC 0.026
GBM 0.071
HNSC 0.179
LUAD -0.889
LUSC 0.053
non_ccRCC -2.327
PDAC 0.279
UCEC 0.43
RUNX1-Thr18
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.305
GBM 1.025
HNSC -0.242
LUAD -1.398
LUSC
non_ccRCC
PDAC
UCEC 0.919
RUNX1-Tyr258
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC 0.707
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
RUNX1-Tyr260
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC -0.552
LUAD -0.602
LUSC
non_ccRCC
PDAC
UCEC 1.154
RUNX1T1-Ser14
Cancer Intensity
BRCA -0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC 0.707
non_ccRCC
PDAC
UCEC
RUNX1T1-Ser390
Cancer Intensity
BRCA 0.407
COAD -0.559
HGSC 1.361
ccRCC -1.198
GBM
HNSC 1.786
LUAD -0.58
LUSC -0.139
non_ccRCC -0.957
PDAC 0.558
UCEC -0.679
RUNX1T1-Thr25
Cancer Intensity
BRCA
COAD
HGSC -0.965
ccRCC
GBM
HNSC -0.066
LUAD
LUSC
non_ccRCC
PDAC 1.032
UCEC
RUNX1T1-Thr565
Cancer Intensity
BRCA
COAD 1.488
HGSC
ccRCC
GBM
HNSC -0.938
LUAD
LUSC -0.915
non_ccRCC
PDAC 0.19
UCEC 0.175
RUNX1T1-Thr568
Cancer Intensity
BRCA
COAD 1.663
HGSC
ccRCC
GBM
HNSC -1.05
LUAD
LUSC -0.138
non_ccRCC
PDAC -0.232
UCEC -0.244

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
R 233 C Acute myelogenous leukemia Methylation 32573733
R 237 C Acute myelogenous leukemia Methylation 32573733
R 223 P Myeloid Methylation 24332853
T 207 U Breast cancer Phosphorylation 32549768
- - U Glioblastoma Ubiquitination 36949071

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: